The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2017
|
| _version_ | 1797052742716358656 |
|---|---|
| author | Kayastha, G Ranjitkar, N Gurung, R Kc, R Karki, S Shrestha, R Rajbhandari, P Thapa, R Poudyal, B Acharya, P Roberts, D Hayes, B Zimmerman, M Basnyat, B |
| author_facet | Kayastha, G Ranjitkar, N Gurung, R Kc, R Karki, S Shrestha, R Rajbhandari, P Thapa, R Poudyal, B Acharya, P Roberts, D Hayes, B Zimmerman, M Basnyat, B |
| author_sort | Kayastha, G |
| collection | OXFORD |
| description | Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance in a cohort of 388 imatinib-treated CML patients (149 Female and 239 male) registered between February 2003 and June 2016 in Nepal. Forty-five patients (11 female 34 male) were studied; 18 different BCR-ABL1 mutations were seen in 33 patients. P-loop mutation, Kinase domain and A-loop mutations were seen in 9, 16 and 4 patients respectively. Other mutations were seen in five patients. A T315I mutation was the most common mutation, followed by F359V and M244V. Sixteen mutations showed intermediate activity to complete resistance to Glivec. Among the 45 patients evaluated for BCR-ABL1 mutations, 4 were lost to follow-up, 14 died and 27 are still alive. Among the surviving patients, 16 are receiving Nilotinib, 5 Dasatinib and 3 Ponatinib, while 3 patients were referred to India, one of who received allogenic bone marrow transplantation. Understanding the spectrum of further acquired mutations in BCR-ABL1 may help to choose more specific targeted tyrosine kinase inhibitors that can be provided by GIPAP. |
| first_indexed | 2024-03-06T18:34:56Z |
| format | Journal article |
| id | oxford-uuid:0ae57794-700f-46e1-b5bf-f2b220d64680 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:34:56Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:0ae57794-700f-46e1-b5bf-f2b220d646802022-03-26T09:26:35ZThe use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0ae57794-700f-46e1-b5bf-f2b220d64680EnglishSymplectic Elements at OxfordWiley2017Kayastha, GRanjitkar, NGurung, RKc, RKarki, SShrestha, RRajbhandari, PThapa, RPoudyal, BAcharya, PRoberts, DHayes, BZimmerman, MBasnyat, BPhiladelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance in a cohort of 388 imatinib-treated CML patients (149 Female and 239 male) registered between February 2003 and June 2016 in Nepal. Forty-five patients (11 female 34 male) were studied; 18 different BCR-ABL1 mutations were seen in 33 patients. P-loop mutation, Kinase domain and A-loop mutations were seen in 9, 16 and 4 patients respectively. Other mutations were seen in five patients. A T315I mutation was the most common mutation, followed by F359V and M244V. Sixteen mutations showed intermediate activity to complete resistance to Glivec. Among the 45 patients evaluated for BCR-ABL1 mutations, 4 were lost to follow-up, 14 died and 27 are still alive. Among the surviving patients, 16 are receiving Nilotinib, 5 Dasatinib and 3 Ponatinib, while 3 patients were referred to India, one of who received allogenic bone marrow transplantation. Understanding the spectrum of further acquired mutations in BCR-ABL1 may help to choose more specific targeted tyrosine kinase inhibitors that can be provided by GIPAP. |
| spellingShingle | Kayastha, G Ranjitkar, N Gurung, R Kc, R Karki, S Shrestha, R Rajbhandari, P Thapa, R Poudyal, B Acharya, P Roberts, D Hayes, B Zimmerman, M Basnyat, B The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title_full | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title_fullStr | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title_full_unstemmed | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title_short | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. |
| title_sort | use of imatinib resistance mutation analysis to direct therapy in philadelphia chromosome bcr abl1 positive chronic myeloid leukaemia patients failing imatinib treatment in patan hospital nepal |
| work_keys_str_mv | AT kayasthag theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT ranjitkarn theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT gurungr theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT kcr theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT karkis theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT shresthar theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT rajbhandarip theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT thapar theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT poudyalb theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT acharyap theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT robertsd theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT hayesb theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT zimmermanm theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT basnyatb theuseofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT kayasthag useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT ranjitkarn useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT gurungr useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT kcr useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT karkis useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT shresthar useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT rajbhandarip useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT thapar useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT poudyalb useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT acharyap useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT robertsd useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT hayesb useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT zimmermanm useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal AT basnyatb useofimatinibresistancemutationanalysistodirecttherapyinphiladelphiachromosomebcrabl1positivechronicmyeloidleukaemiapatientsfailingimatinibtreatmentinpatanhospitalnepal |